Last reviewed · How we verify

NCT04503109: nPower™-US

Spinal Cord Stimulation in the Treatment of Chronic, Intractable Pain Using the Nalu™ Neurostimulation System

Completed NA Last updated 15 February 2023
What this trial tests

NA trial testing Nalu Neurostimulation System in Pain, Chronic in 110 participants. Completed in 13 September 2022.

Timeline
16 July 2020
Primary endpoint
13 September 2022
13 September 2022

Quick facts

Lead sponsorNalu Medical, Inc.
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment110
Start date16 July 2020
Primary completion13 September 2022
Estimated completion13 September 2022
Sites8 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

Nalu Medical, Inc. — full company profile →

Who can join

Adults 21 to 80, any sex, with Pain, Chronic or Pain, Intractable. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The Nalu Neurostimulation System is capable of delivering multiple therapy options to address patient needs. The study will confirm the efficacy, safety, comfort and compliance with the Nalu Neurostimulation System in adult subjects with chronic pain in the legs and back. Patients who have been diagnosed with failed back surgery syndrome (FBSS) and meet other study eligibility criteria will be enrolled in the study to receive the Nalu Neurostimulation System.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Pain, Chronic

Currently open trials in the same condition.

Other Nalu Medical, Inc. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04503109.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing